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The effects of huntingtin-lowering: what do we 
know so far?
william F Kaemmerer1  
Richard C Grondin2
1CGTA Research Group, eagan, MN, 
USA; 2Department of Neuroscience, 
University of Kentucky Medical 
Center, Lexington, KY, USA
Abstract: Therapies targeting mutant huntingtin DNA, mRNA, and protein have a chance at 
becoming the first disease-modifying treatments for Huntington’s disease, a fatal inherited neuro-
degenerative disorder for which only symptom management treatments are available today. This 
review focuses on evidence addressing several key questions pertinent to huntingtin-lowering, 
ranging from the functions of wild-type huntingtin (wtHTT) that may be disrupted by huntingtin-
lowering treatments through the various ways huntingtin can be lowered, the tolerability of wtHTT-
lowering in mice and primates, what has been found in the Ionis Pharmaceutical safety trial of a 
huntingtin-lowering therapy, and to the question of how much mutant huntingtin may need to be 
lowered for a therapy to be clinically effective. We conclude that adverse consequences of lowering 
wtHTT in animals appear to be brain region-specific, and/or dependent upon the animal’s stage 
of development and the amount by which huntingtin is lowered. Therefore, safe approaches to 
huntingtin-lowering in patients may be to lower huntingtin only moderately, or lower huntingtin 
only in the most affected brain regions, or lower huntingtin allele-selectively, or all of the above. 
Many additional questions about huntingtin-lowering remain open, and will only be answered 
by upcoming clinical trials, such as whether the delivery approaches currently planned will be 
adequate to get the treatment to the necessary brain regions, and whether non-allele-selective 
huntingtin-lowering will be safe in the long run. Meantime, there is a role for preclinical research 
to address key knowledge gaps, including the effects of non-allele-selective huntingtin-lowering 
on protein trafficking and viability at the cellular level, the tolerability of wtHTT-lowering in the 
corticostriatal connections of the primate brain, and the effects of this lowering on the functioning 
of neurotransmitter systems and the transport of neurotrophic factors to the striatum.
Keywords: Huntington’s disease, huntingtin-lowering, gene therapy, cortex, striatum, CAG 
repeat disorder
Introduction
Huntington’s disease (HD) is an inherited, fatal disorder in which the primary pathology 
is neurodegeneration, particularly cortical thinning and atrophy of the caudate nucleus 
and putamen. The disease is caused by the expansion of a CAG repeat region in exon 
1 of the HTT gene, resulting in the expression of an expanded, mutant huntingtin 
protein (mHTT). Individuals with just one HTT allele containing more than 40 CAG 
repeats are invariably affected by the disease, while individuals with fewer than 36 
CAG repeats on both alleles do not manifest the disease.1,2 The age of symptom onset 
is inversely related to the number of CAG repeats and influenced by genetic modifier 
loci on chromosomes 8 and 15.3,4 No disease-modifying treatment yet exists.
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Studies in cells and animal models of HD have found 
mHTT to have a myriad of disruptive effects, including tran-
scriptional dysregulation, impairment of protein degradation 
systems, mitochondrial dysfunction, and altered synaptic 
plasticity.5 Some treatments targeting downstream effects 
of mHTT have shown efficacy in animal models of HD, 
but none have shown efficacy in the human disease today. 
Consequently, the best approach to treatment appears to be 
the targeting of huntingtin itself, seeking to eliminate or at 
least lower the expression of mHTT. In principle, this can be 
accomplished by various technologies, including intrabodies 
targeting the huntingtin protein, antisense oligonucleotides 
(ASOs) or RNAi agents targeting the mRNA transcripts, 
zinc-finger repressors to prevent mRNA transcription, or gene 
editing of HTT DNA itself. With the exception of the latter 
approach, these techniques will reduce but not completely 
eliminate the production of mHTT. Therefore, the term 
“huntingtin-lowering” is the preferred term for this class of 
potential therapies. As discussed later in this review, the first 
trial of a huntingtin-lowering agent in patients has recently 
been completed by Ionis Pharmaceuticals, showing via an 
assay for mHTT in the cerebrospinal fluid (CSF) that lower-
ing of HTT was achieved and there were no adverse events 
attributable to the agent.
Although many questions will only be answered by clini-
cal trials, it is of interest to review what has been learned 
about the effects of huntingtin-lowering since the discovery 
of the HTT gene in 1993. This review focuses on key ques-
tions regarding the rationale, safety, possible efficacy, and 
possible side-effects of huntingtin-lowering as a treatment 
for HD, surveying the empirical evidence that bears on these 
questions.
is lowering the expression of mHTT 
protein the right objective?
HD is due to toxic properties of mHTT rather than just loss 
of wild-type huntingtin (wtHTT) function. While wtHTT is 
necessary in early life (knockout of the mouse homologue 
of huntingtin is embryonically lethal6–8), individuals lacking 
wtHTT because both their alleles contain an expanded CAG 
repeat region can be healthy for decades.
Could provision of “extra” wtHTT to a patient be a thera-
peutic option? In neuronal and non-neuronal cells transfected 
with mHTT, co-transfection of wtHTT significantly reduces 
cell death.9 In mice with a yeast artificial chromosome (YAC) 
for mutant human huntingtin, a pro-apoptotic effect of mHTT 
on cells in the testes is completely inhibited in mice that are 
hemizygous or homozygous for wild-type murine huntingtin 
(Htt).10 YAC18 mice overexpressing a normal repeat length 
transgene (18 CAGs) are protected against neurodegen-
eration induced by striatal injection of quinolinic acid.11 
However, other evidence indicates that a treatment based on 
supplementing wtHTT expression would be insufficient. A 
genetic cross of YAC128 mice (128 CAGs) and YAC18 mice 
produces offspring that overexpress wtHTT in the context 
of mHTT. Though these offspring have mild improvement 
in striatal cross-sectional area compared to YAC128 mice, 
they show no significant improvement in motor coordina-
tion, striatal volume, striatal neuronal numbers, or striatal 
DARPP-32 expression.12
Is the mHTT protein the only pathogen in HD? Some loss 
of wtHTT function and possible effects of protein products 
produced by repeat-associated non-ATG (RAN) translation 
of the expanded mRNA have been hypothesized to also play 
a role in the disease. Products of RAN translation from mHTT 
mRNA have been found in HD human brains, and the toxic-
ity of expanded HTT exon1 mRNA in human neuroblastoma 
cells can be blocked by anti-CAG small RNA.13 Intrastriatal 
injection of a locked nucleic acid consisting of CTG repeats 
(complementary to CAGs) induces rapid motor improvement 
in the R6/2 mouse model of HD without lowering either 
mHTT or wild-type protein levels in these mice.14 Therefore, 
while lowering of mHTT is essential, huntingtin-lowering 
therapies utilizing agents that target HTT at the mRNA level 
(ASOs and RNAi agents) might be more advantageous than 
those that act only on the protein product (eg, anti-huntingtin 
intrabodies). However, for these agents, consideration must 
be given to the potential for the agent to target other genes 
and transcripts besides HTT, producing “off-target” effects. 
Although recommended by the Oligonucleotide Safety Work-
ing Group,15 in silico approaches to predicting the off-target 
effects and toxicity of ASOs based on their sequence16 are 
not perfect. Therefore, ASO developers utilize a combination 
of in silico screening, in vivo screens for liver toxicity, and 
transcriptome-wide evaluations of gene suppression to identify 
lead candidates.17 Developers of RNAi agents expressed from 
DNA delivered by a viral vector rely heavily on in vitro and 
in vivo screening of candidate sequences, because chemical 
modification is not available as a way to improve any inad-
equate specificity of a chosen candidate.
Different types of huntingtin-lowering therapies also 
differ in their advantages and disadvantages with regards to 
route of delivery, longevity of effect, reversibility, control of 
dosing, etc. See Wild and Tabrizi18 for a review.
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Can HTT-lowering be accomplished allele 
specifically if necessary?
Ever since it was determined that huntingtin protein is 
required for embryogenesis6–8 and early development,19 
consideration has been given to the possibility of lowering 
expression of the mutant huntingtin allele while preserving 
expression of wtHTT in heterozygous individuals. Many 
approaches have proven feasible in cell and animal models 
of HD. Because a single nucleotide mismatch between an 
siRNA and a complementary mRNA can substantially reduce 
its RNAi activity, an siRNA targeting a single-nucleotide 
polymorphism (SNP) site in HTT in a heterozygous cell can 
reduce expression of the allele with the matching nucleotide 
of the SNP while leaving expression of the other allele much 
less affected. van Bilsen et al20 designed siRNA targeting 
SNPs in the HD gene and identified siRNA that are allele-
selective in reducing HTT in fibroblasts from heterozygous 
HD patients. They also developed a simple method for 
identifying which SNP variant is on the same allele as the 
expanded CAG repeat allele using SNP variant-specific 
primers for the reverse transcription step of an RT-PCR assay. 
Subsequently, Zhang et al21 demonstrated allele specificity 
using an siRNA targeting a polymorphic deletion (Δ2642) 
linked to the CAG repeat allele in HD fibroblasts. Carroll et 
al22 identified numerous ASOs that are potent and selective 
for their respective SNP target in vitro and in vivo when 
injected into the brains of transgenic mouse models of HD.
A disadvantage of leveraging SNPs to achieve allele 
specificity in huntingtin-lowering is that there is currently no 
known single SNP that can be used as the basis for an allele-
specific therapy in all HD patients. Genotyping followed by 
combinatorial analysis of the frequency and co-occurrence 
of 26 SNP sites on the alleles of 327 unrelated European 
Caucasian HD patients showed that a repertoire of seven 
allele-specific siRNAs would be needed for 85.6% of those 
patients to be treatable by at least one of the siRNA.23 A simi-
lar analysis sequencing 22 SNP sites in 225 HD samples led 
to the estimate that 5 siRNAs targeting 3 SNPs could provide 
therapy for 75% of the US and European HD populations.24 
Although encouraging, these findings are still daunting with 
regards to the cost of developing and achieving regulatory 
approval for multiple agents.
Could an allele-specific agent be found that would apply 
to all patients? Initial attempts to use ASOs to target the 
expanded CAG repeat itself achieved only modest allele 
selectivity.25 However, advances in chemically modified oli-
gonucleotides and the use of multiple mismatches within an 
agent’s sequence has led to the identification of ss-RNAs that 
can inhibit the translation of mHTT with high potency and 
selectivity.26 The ss-RNAs can distinguish between 44 CAG 
repeats and 15 CAG repeats on the alleles of patient-derived 
cells (GM04719); however, many patients have a difference 
between the repeat lengths of their alleles that is smaller 
than this (44 CAGs is the median number found in patient 
samples).2 Also, these agents might have off-target effects, 
lowering expression of other genes that contain CAG repeats.
Another option for targeting the CAG repeat region is 
the use of zinc-finger proteins (ZFPs).27 Using a repressor 
element targeted to the CAG repeat region of the HD gene 
with ZFPs that bind CAGs, Zhang et al28 achieved about 
90% repression of mHTT expression with minimal effect 
on normal CAG length alleles in fibroblasts derived from 
HD patients. In another approach, Garriga-Canut et al29 
screened long ZFP chains designed to bind both the CAG 
and complementary GTC strand of long HD repeat regions 
more strongly than shorter repeat regions. In a cell line from 
a knockin model of HD (STHdhQ7/Q111), these ZFPs fused with 
a Kox-1 repressor element reduced mutant huntingtin mRNA 
by almost 80% and mutant protein expression by 95% while 
reducing neither protein nor RNA produced from the wild-
type allele (Q7). Both investigators found their ZFPs function 
in vivo to improve the phenotype of the R6/2 mouse model 
of HD.28,29 However, further development of these entities 
toward clinical trials has not yet been reported.
Finally, another way to lower huntingtin allele specifically 
may be to use CRISPR/Cas9 editing to delete DNA from the 
mutant allele. Allele-specific gene editing can occur if the 
single-stranded guide RNA used with Cas9 targets a SNP 
site whereby one of the SNP variants either eliminates a 
protospacer-adjacent motif (PAM) sequence (on the allele 
to be preserved) or creates a PAM sequence (on the allele to 
be edited). Monteys et al30 found that appropriately designed 
sgRNA applied in pairs can result in allele-specific deletion 
of genomic DNA spanning the 5′UTR and exon-1 of HTT in 
heterozygous patient-derived fibroblasts in vitro and reduce 
human mHTT expression in a BACHD mouse model of HD 
to 40% in vivo. Similarly, Shin et al31 used sgRNA to selec-
tively excise 44 kilobases of DNA spanning the promoter 
region, transcription start site, and first three exons of HTT. 
However, both approaches have the disadvantage that the 
allele specificity depends upon SNPs in the HD gene, so no 
single therapeutic agent would be applicable to all patients. 
Of greater concern is the recent finding that gene editing 
based on the dsDNA breaks produced by Streptococcus 
pyrogenes Cas9 (SpCas9) can result in a wide variety of 
unintended editing events, including large deletions that 
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are non-contiguous with the targeted cut site.32 This safety 
issue might be avoided using variants of Cas9 (nickases) that 
produce single-stranded cuts in the DNA rather than dsDNA 
breaks. Using such nickases, Dabrowska et al33 demonstrated 
that the CAG repeat region can be precisely excised from 
the HTT gene by targeting two sites, one at the 5′ end of the 
CAG repeat and the other about 40 bases downstream of the 
3′ end of the repeat. However, the excision is independent on 
CAG repeat length, and thus is not allele specific. Substantial 
additional research will be needed to develop a CRISPR/Cas9 
agent that is allele specific and safe for in vivo human use.
Of note, one allele-specific approach to lowering hunting-
tin using oligonucleotides targeting SNP sites has advanced 
to clinical trials. Patients are being recruited for two trials 
(NCT03225833 and NCT03225846, Wave Life Sciences, 
Ltd.) each using an oligonucleotide targeting one of the more 
prevalent SNPs in the HD gene. However, other companies 
investing in HD therapy development have opted for non-
allele-specific approaches.
what functions of wtHTT may be 
disrupted by non-allele-specific 
huntingtin-lowering?
Concerns that lowering wtHTT in patients may have undesir-
able consequences have arisen from studies identifying many 
functions of the normal protein. These have roles not only in 
development but also in regulation of intracellular traffick-
ing processes, formation of cortical and striatal excitatory 
synapses, and in transcriptional regulation (for a review, see 
Jimenez-Sanchez et al5). In vitro, wtHTT protects striatal-
derived cells from mitochondrial toxins.34 Both in vivo and 
in vitro, wtHTT is phosphorylated in response to DNA dam-
age, suggesting a role in the DNA damage response signal.35 
Proteomic analyses have identified hundreds of proteins 
that interact with wtHTT,36 supporting a view of HTT as a 
scaffolding protein involved in numerous protein–protein 
interactions. 
wtHTT is also involved in many types of trafficking in 
cells, including bidirectional transport of vesicles in neu-
rons,37 trafficking between Golgi and extracellular space,38 
transport via endocytic and secretory pathways,39 and secre-
tory vesicle fusion at the plasma membrane40 where loss of 
wtHTT results in ~50% decrease in the number of vesicle 
fusion events per unit time. Investigations of wtHTT interac-
tion with dynein and dydactin41 have led to the proposal of 
models whereby wtHTT plays a global role in vesicle and 
organelle transport throughout the cytoskeletal network.42
The wide variety and apparent centrality of the functions 
of wtHTT (see Liu and Zeitlin43 for a detailed review) have 
led to the question of whether HTT could be indispensable 
in the adult brain. If so, excessive non-allele-specific lower-
ing of huntingtin may not be safe. What evidence exists to 
inform this issue?
what evidence is there concerning the 
safety of lowering wtHTT?
wtHTT-lowering may not be safe in the developing 
brain
In a study of mice with one null copy of Hdh and one copy 
altered to express Htt at a greatly reduced level (~15% of 
endogenous levels), the mice were small from birth and 
had movement abnormalities and variable increases in 
cerebroventricular volume.44 Studies using Cre-mediated 
conditional knockout of Hdh in mice have shown that 
knockout of Hdh at various stages of embryonic and post-
natal development results in deficiencies in cortical neuron 
migration,45 abnormalities in cortical and striatal synaptic 
development,46 and behavioral and neurological abnormali-
ties that are not reversed by later restoration of ~50% Htt 
expression (at P21).47
in vitro evidence related to the safety of wtHTT-
lowering
Much evidence giving rise to safety concerns about hun-
tingtin-lowering comes from in vitro studies, particularly 
those identifying a role wtHTT plays in the production and 
transport of brain-derived neurotrophic factor (BDNF) and 
BDNF mRNA.48 Wild type but not mHTT promotes cortical 
BDNF gene transcription by inhibiting the BDNF silencing 
activity of the neuron restrictive silencer element.49 Hunting-
tin interacts indirectly with the REST/NRSF-interacting LIM 
domain protein through dynactin;50 in the case of mHTT, this 
interaction is weaker. This is consistent with the finding that 
BDNF mRNA and protein levels are reduced in HD.51 Fur-
ther reduction due to non-allele-specific huntingtin-lowering 
could jeopardize the survival of medium spiny neurons of 
the striatum, which are dependent upon cortically derived 
BDNF52and particularly vulnerable in HD. In neuroblastoma 
cells, reduction of HTT by siRNAs reduces the velocity of 
vesicle transport and increases the time vesicles spend with-
out moving.53 Her et al54 studied primary cortical neurons 
from Hdh floxed mice and found that complete knockout of 
Htt from these cortical neurons did not affect their viability, 
but reduced both anterograde and retrograde transport of 
 
D
eg
en
er
at
iv
e 
N
eu
ro
lo
gi
ca
l a
nd
 N
eu
ro
m
us
cu
la
r 
D
is
ea
se
 d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
16
3.
8.
74
 o
n 
04
-O
ct
-2
01
9
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Degenerative Neurological and Neuromuscular Disease 2019:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
7
Kaemmerer and Grondin
particles in their axons. Interestingly, they also found that 
axonal transport of BDNF was not affected in primary corti-
cal neurons transfected with mHTT.54
Caviston et al41 have found that reduction of HTT pro-
tein by 83% in HeLa cells results in the Golgi becoming 
stretched out or vesicular in these cells, disrupting protein 
transport particularly of proteins destined for the extracel-
lular compartment. This consequence may not arise in 
huntingtin-lowering treatments using agents that do not 
achieve this extent of HTT reduction, but could arise in 
treatments involving gene editing. The clinical relevance of 
this effect may depend upon whether, in the long-term, there 
are compensatory adaptations in cells that would mitigate 
this disruption of the Golgi.
in vivo evidence regarding the safety of wtHTT-
lowering in adults: mouse studies
At least three studies have investigated the consequences 
of complete knockout of Htt in adult mice at various 
ages, with conflicting conclusions. Wang et al55 crossed 
conditional Hdh knockout mice56 with mice that express a 
tamoxifen-inducible Cre, producing inducible Htt knockout 
mice. Depletion of Htt in mice by tamoxifen injection at 
2 months of age resulted in 95% mortality due to acute 
pancreatitis. In contrast, 95% of mice in which Htt was 
depleted at 8 months of age survived long term (studied 
for 10–11 more months) with no significant differences in 
rotarod performance, body weight, or the expression of 
various proteins (LC3I/II, P62, caspase-3, NfκB, FAT10) 
in the brain and peripheral tissues. They also crossed floxed 
Hdh mice with transgenic mice expressing Nestin-CreER, 
producing mice in which tamoxifen injection eliminated 
Htt expression in neurons and not peripheral tissues. These 
mice, injected with tamoxifen at 2, 4, or 8 months of age, 
showed no differences in brain volume or histology, and 
no differences over 7–8 months time in post-injection body 
weight, rotarod performance, or gripping ability compared 
to heterozygous Hdh knockout controls. These results sug-
gest that lowering and even elimination of wtHTT may be 
safe if depletion of wtHTT occurs only in the brain or only 
in older individuals.
However, a study by Dietrich et al57 produced distinctly 
different results. In their study, CAG-CreER mice were 
first crossed with heterozygous knockout mice (Hdh+/-) and 
offspring were subsequently crossed with Hdhflox/flox mice, 
producing CreER;Hdhflox/- mice, termed cKO mice. These 
cKO mice express ~50% of the level of endogenous Htt 
compared to wild-type mice from conception. Administra-
tion of tamoxifen to cKO mice results in nearly complete 
elimination of Htt expression (evaluated by Western blot), 
reduction in Htt mRNA in total brain extracts to <15% of 
wild-type levels (evaluated by RT-PCR), and reduction 
of Htt expression in the cortex and striatum to <20% of 
wild-type levels (evaluated by electrochemiluminescence 
assay). Regardless of when tamoxifen was administered 
to these mice (at age 3, 6, or 9 months), the mice devel-
oped progressive gait abnormalities, resting tremors, and 
substantially reduced rotarod performance within 1–3 
months after huntingtin-lowering. They also had a short-
ened life span compared to cKO mice not administered 
tamoxifen. No pancreatitis was reported in this study in 
mice administered tamoxifen at 3 months of age, although 
other adverse effects of huntingtin-lowering were observed 
in peripheral tissues, including thickening of the cornea 
observed in about one-third of tamoxifen-treated cKO mice 
and testicular atrophy seen in tamoxifen-treated males. 
Histologically, the most pronounced findings were early 
development of reactive gliosis in the cerebellum and 
thalamus within 3 months of huntingtin-lowering and later 
development of calcification in the thalamus (seen as early 
as 13 months of age and confined to the thalamus). Ferric 
iron levels were significantly reduced throughout the brains 
of tamoxifen-treated cKO mice, including in the striatum 
and cortical neuronal cells. Conversely, although reactive 
gliosis was seen in the striatum 9 months after huntingtin-
lowering, no overt loss of cells was observed in the cortex 
even 14 months after huntingtin-lowering, and no change 
in DARPP-32 expression or overt cell loss was seen in the 
striatum 12 months after huntingtin-lowering. Overall, 
these observations suggest that huntingtin-lowering may 
be tolerated in the striatum and cortex more than in other 
regions of the brain.
A third study of huntingtin-lowering in the adult mouse was 
performed by Pla et al58 These investigators crossed CaMK-
CreER mice (in which tamoxifen activation of Cre recombinase 
occurs only in mature cortical and hippocampal neurons) with 
Hdhflox/flox mice to obtain offspring in which Hdh was inactivated 
in these neurons by administering tamoxifen to the mice at 2 
months of age. Six months later, investigation of hippocampal 
neurogenesis in the dentate gyrus of the mice showed impaired 
maturation and differentiation of newborn neurons (assessed by 
dendritic arborization) and reduced survival of newborn neu-
rons. These mice showed no obvious motor deficits in rotarod 
tests, but spent significantly less time than controls in the center 
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of an open field and less time in open arms of an elevated plus 
maze, indicative of an anxious phenotype. Western blotting 
of protein extracts from the hippocampi of the mice indicated 
that although BDNF levels were no different from controls, 
Erk and Akt (kinases involved in intracellular signaling upon 
BDNF binding to cell surface receptors) were less extensively 
phosphorylated in the tamoxifen-treated mice than in controls. 
This suggests that BDNF signaling was impaired due to a 
reduction in BDNF transport or release. The investigators sug-
gest that some of the anxiety disorders prevalent among HD 
patients may be caused by loss of normal HTT function in the 
hippocampus and cortex, particularly with regards to BDNF 
transport, due to a dominant negative effect of mHTT (although 
Her and Goldstein54 did not find a dominant negative effect of 
mHTT in BDNF transport in primary cortical neurons). 
It is difficult to reconcile the results of these three stud-
ies. Wang et al did not report testing their mice for behavior 
indicative of an anxious phenotype; Dietrich et al did not 
find pancreatitis or dramatically early mortality in their 
conditional cKO mice treated with tamoxifen at 3 months 
of age in contrast to the findings of Wang et al in mice 
treated at 2 months of age; Wang et al did not observe the 
progressive behavioral deficits, thalamic calcifications, or 
other adverse effects of huntingtin elimination or lowering 
reported by Dietrich et al. Barring procedural, environmen-
tal, or genetic background differences, the best explanation 
might be that, as noted by Dietrich et al, the effects of Htt 
elimination may be more deleterious in a mouse that has 
had only 50% of normal endogenous levels of Htt in its life 
prior to Htt elimination (in their study) than in a mouse with 
normal levels of Htt prior to tamoxifen administration (in 
the Wang et al study). 
in vivo evidence that wtHTT-lowering in adulthood is 
tolerated: non-human primate studies
We and others have studied the effects of lowering wild-type 
Htt in non-human primates whose neurophysiology, basal 
ganglia anatomy, and behavioral repertoire more closely 
resembles that of humans. McBride et al59 stereotactically 
injected 10–12 µL of 1E12 vg/mL AAV2/1 encoding a 
huntingtin-lowering miRNA (miHDS1) into each of three 
sites in the putamen in one hemisphere of adult male rhesus 
macaques (n=4). Animals were assessed pre- and post-
operatively on general behavior and motor skill assays and 
euthanized 6 weeks post-AAV administration for molecular 
and histological analyses. AAV-miHDS1-injected recipients 
showed a significant 45% reduction in wild-type Htt mRNA 
expression in the putamen compared to animals that received 
a control miRNA. Compared to controls, AAV-miHDS1-
injected animals showed no motor skill deficits, no significant 
decrease in the mRNA for DARPP-32 (a marker for medium 
spiny neurons), and no loss of NeuN-positive neurons in the 
putamen.
We conducted a much longer study in rhesus macaques60 
using bilateral injections of a larger quantity and higher titer 
of AAV. Adult females were injected bilaterally with 2E12 
vg/mL of either AAV2-HD5 (a huntingtin-lowering shRNA, 
n=4) or AAV2-CTRL5 (a scrambled shRNA, n=4) into 
three sites per hemisphere, one in the caudate (30 µL) and 
two in the putamen (60 µL each). Six months later, shRNA 
transcripts were detected in the targeted brain regions, and 
HD5 vector recipients showed a 30% reduction in wtHtt 
mRNA and an average wtHtt protein reduction of 45% 
(range 32%–67% reduction) relative to controls. Home-cage 
activity levels and motor performance on an automated 
hand-retrieval task were not adversely affected by either 
AAV2-HD5 or CTRL5 delivery. Motor memory was also 
preserved as all animals recalled and performed the retrieval 
task without intervening practice between the monthly test 
sessions. There was no significant effect on immunostaining 
for DARPP-32, and no discernible neuronal loss or abnor-
mal astrocytosis noted in any of the animals upon blinded 
microscopic evaluation by a board-certified pathologist. Our 
study therefore showed that 32%–67% reduction of wtHtt is 
safe and well-tolerated in the primate caudate and putamen 
for at least 6 months.
In addition to using viral vectors, our group has also 
evaluated the use of programmable pumps and intraparen-
chymal catheters to chronically deliver huntingtin-lowering 
siRNA directly into the rhesus striatum.61,62 Intraparenchy-
mal catheters were implanted unilaterally into the right puta-
men of adult, female rhesus monkeys and connected to an 
abdominally implanted pump from which siRNA (or PBS, 
in controls) was delivered. Continuous infusion of siRNA 
for 28 days was well-tolerated and resulted in up to 75% 
lowering of Htt mRNA in individual brain tissue samples, 
and ~45% suppression of Htt mRNA on average throughout 
most of the rhesus striatum. Decreased neuronal levels of 
Htt protein were indicated by a pronounced attenuation of 
immunostaining intensity in the putamen of siRNA recipi-
ents. No behavioral changes were observed. Microscopic 
evaluations conducted on Fluoro-Jade B-stained brain sec-
tions did not reveal any continuing neuronal necrosis in any 
of the control or siRNA-treated animals. Normal patterns 
of Nissl-stained neurons were retained in corresponding 
brain regions.
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Together, these results support the feasibility and safety 
of wtHtt reduction in the primate brain. In addition, Ambrose 
et al63 have noted a case in humans of a phenotypically normal 
female in whom the HD locus was bisected by a balanced 
translocation, indicating that heterozygous disruption of HTT 
from conception onward was fully tolerated in this individual. 
It should be noted, however, that it is possible that the toler- 
ability of wtHTT reduction may be different in patients in 
the context of mHTT expression, and that the time required 
for a reduction in wtHtt to have ill effects in primates may 
be longer than the primate studies reported so far. 
what has been learned about huntingtin-lowering in 
large animal models of HD?
Because of the inherent limitations of rodent models of HD, 
including but not limited to basal ganglia anatomy, brain size, 
and lifespan, there has been interest in developing transgenic 
models of HD in sheep, minipigs, and non-human primates. 
These larger animals have a longer pubertal age and gesta-
tion time, so breeding can be a slow and expensive process, 
especially in primates. Data from only five male and three 
female transgenic HD monkeys have been reported to date.64 
The three females had a severe motor phenotype necessitating 
euthanasia within a month of birth.65 A longitudinal study of 
four males showed deterioration of motor and cognitive skills 
with age and enlargement of lateral ventricles as seen in the 
human disease.66 However, the small numbers of these ani-
mals has precluded extensive studies of huntingtin-lowering 
in these transgenic primates.
Conversely, a limitation for the use of transgenic sheep 
and minipigs so far is that they have been slow in develop-
ing a clear disease-related phenotype.67–69 For example, only 
sparse cortical mHTT aggregates were found in 18-month-old 
transgenic sheep along with nuclear inclusions in these sheep 
at 36 months of age.70 At the age of 24 months, transgenic 
minipigs have modest neuropathological changes, including 
moderate microglial activation in the caudate and mHTT 
fragments (but not aggregates) in the cytoplasm of striatal 
and cortical cells, but remain asymptomatic.71 A recently 
developed CRISPR/Cas9 knockin pig model may more 
closely recapitulate HD features including gait abnormali-
ties, enlarged lateral ventricles, and degeneration of striatal 
medium spiny neurons.72
To date, few studies of huntingtin-lowering in these larger 
transgenic models of HD have been reported. Pfister et al73 
stereotactically injected the striatum of 8- to 14-month-old 
transgenic sheep expressing full-length human HTT with 
AAV9 encoding an artificial miRNA targeting the transgene. 
The treatment reduced human mHTT mRNA and protein by 
50%–80% in the striatum at 1 and 6 months post-injection, 
but not endogenous levels of sheep Htt protein. There was no 
significant loss of striatal neurons at 6 months after treatment, 
and Iba1-positive microglia levels were comparable to con-
trols suggesting that safe and sustained silencing of human 
mHTT protein can be achieved in a large animal’s brain by 
direct delivery of an AAV carrying an artificial miRNA. 
Similarly, bilateral administration of AAV5-miHTT in 20- 
to 39-month-old transgenic minipigs significantly reduced 
human mHTT mRNA and protein in the putamen (by 47.5% 
and 53.0%, respectively), caudate nucleus (by 44.2% and 
50.5%, respectively), and thalamus (by 72.8% and 53.5%, 
respectively) 3 months following a single injection into both 
the putamen and thalamus.74 The AAV5-miHTT treatment 
did not significantly increase microglial expression or alter 
DARPP-32 staining of medium spiny neurons. These studies 
support the translation of AAV-delivered huntingtin-lowering 
therapies to the clinic, but neither one was informative with 
regards to the effect of the treatment on any disease pheno-
type of the animal. Also, since endogenous huntingtin was 
not targeted by these therapeutic agents, additional studies 
will be needed to address the tolerability of total huntingtin-
lowering in these larger transgenic models of HD.
A summary of animal studies regarding the tolerability of 
the lowering of wtHTT protein by genetic means vs adminis-
tration of a huntingtin-targeting agent, at different ages, and 
by various amounts, is provided in Table 1.
The apparent tolerability of wtHTT-lowering in adult 
animals, particularly primates, has led many organizations 
to develop therapies for clinical use to focus on total hun-
tingtin-lowering with non-allele-specific agents. Compared 
to allele-specific approaches requiring multiple agents and 
associated diagnostic kits for selecting the appropriate agent 
for a given patient, a non-allele-specific approach may cost 
less to develop and be easier to deploy.
Non-allele-specific therapy development efforts include 
those by Ionis Pharmaceuticals in collaboration with Hoff-
man-La Roche to develop a huntingtin-lowering therapy 
using ASOs, as well as efforts by uniQure, Inc., and by 
Voyager Therapeutics in collaboration with Genzyme to 
develop AAV-delivered RNAi agents. The Ionis Pharmaceu-
ticals’ first clinical trial of a non-allele-specific huntingtin-
lowering agent has been completed. Despite the potential 
safety concerns that could be raised based on preclinical 
studies of the function of wtHTT and the effects of non-
allele-specific lowering in animals, this trial was successful. 
What was learned?
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What has the first trial of a non-allele-
specific HTT-lowering treatment shown 
in patients?
The Phase I/IIa trial of IONIS-HTT
RX
 (NCT02519036), 
completed in November 2017, was a randomized, placebo-
controlled, dose-escalation trial of the safety and tolerability 
of IONIS-HTT
RX
 delivered by intrathecal injections via 
lumbar puncture to patients with early HD.75 Five patient 
cohorts were enrolled, with treated patients receiving four 
monthly doses of 10, 30, 60, 90, or 120 mg of ASO per 
injection, respectively. Patients were followed for 4 months 
after their last injection. The treatment was found to be 
safe and well-tolerated at all doses tested, with no serious 
adverse events in patients receiving the ASOs. Importantly, 
a dose-dependent reduction in mHTT in the patient’s CSF 
was observed in CSF samples taken just prior to the drug 
Table 1 Tolerability studies of huntingtin-lowering in animals
Investigators/
reference
Species/
model
Mode of 
reduction
Amount of wtHtt 
lowering
Age at time of 
wtHtt lowering
Was wtHtt lowering 
well-tolerated?
Auerbach et al44 Mouse Genetic >85% knockout Conception No
Arteaga-Bracho 
et al47
Mouse Genetic (via Cre) Knockout During development 
(< P21)
No
wang et al55 Mouse Genetic (via Cre) Knockout
Knockout
Neuronal knockout
Neuronal knockout
Neuronal knockout
2 months age
8 months age
2 months age
4 months age
8 months age
No 
Yes 
Yes 
Yes 
Yes
Dietrich et al57 Mouse Genetic (via Cre) 50% reduction then 
knockout at:
or knockout at:
or knockout at:
From conception
3 months age
6 months age
9 months age
Yes 
No 
No 
No
Pla et al58 Mouse Genetic (via Cre) Knockout in cortical and 
hippocampal neurons
2 months age No
McBride et al59 Male rhesus miRNA 45% wtHtt reduction 
(striatum)
Adult Yes (for at least 6 weeks)
Grondin et al60 Female 
rhesus
shRNA 45% wtHtt reduction 
(striatum)
Adult Yes (for at least 6 months)
Stiles et al61 Female 
rhesus
siRNA 45% wtHtt reduction 
(striatum)
Adult Yes (for at least 28 days)
Pfister et al73 Sheep miRNA No wtHtt reduction Adult Not applicable
evers et al74 Minipig miRNA No wtHtt reduction Adult Not applicable
Kordasiewicz 
et al81
BACHD MoHuASO 83% wt mRNA reduction 2 months age Yes (for at least 16 weeks)
 BACHD MoHuASO 25% wtHtt reduction 2 months age Yes (for at least 10 
months)
 wild-type 
mouse
MoHuASO 75% wtHtt reduction 2 months age Yes (for at least 4 months)
 Rhesus MkHuASO 53% mRNA reduction
(frontal cortex)
Adult Not reported
Stanek et al82 YAC128 ASO 55% wtHtt reduction 
(striatum)
2 months age Yes (for at least 3 months)
 Abbreviations: wt, wild type; ASO, antisense oligonucleotide.
administration at each month, and again in a follow-up 
lumbar puncture. The extent of wtHTT-lowering was not 
determined, because so far there is no assay available for 
measuring total HTT protein in human CSF. In the highest 
dose cohort, mHTT was lowered by an average of just under 
40% relative to the patient’s baseline level. In a majority of 
the patients receiving IONIS-HTT
RX
, the amount of mHTT 
in the CSF was continuing to decline at the time of the last 
treatment, suggesting that further monthly treatments could 
lead to further reduction in mHTT.
However, there are limitations to the conclusions that can 
be drawn from the trial. As a trial primarily concerned with 
safety, it involved a small number of patients and a short dura-
tion (4 months) of therapy administration. Strictly speaking, 
the main conclusions afforded by the trial are that the treat-
ment was safe for the duration of the study and follow-up, and 
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the treatment produces a reduction of mHTT in the CSF. How-
ever, as a double-blind, placebo-controlled trial in patients, 
the data from the trial merit considerable weight among the 
body of evidence about huntingtin-lowering available so far. 
Potential challenges for this therapy going forward are the 
long-term tolerability of the monthly intrathecal deliveries 
(over half of the patients experienced pain and/or post-lumbar 
puncture syndrome due to the procedure), and patient-to-
patient variability in the effect of the treatment delivery with 
regards to mHTT-lowering. Although the mean lowering of 
mHTT in the CSF of the patients in the highest dose cohort 
was ~40% reduction from baseline, the range was extensive, 
including a paradoxical ~20% increase in mHTT over baseline 
in one patient. Nevertheless, an average reduction of 40% is 
encouraging, and Roche is currently planning for a larger and 
longer pivotal trial to determine the efficacy and continued 
safety of IONIS-HTT
RX
 (RG6042) in HD patients. All par-
ticipants who took part in the Phase I/IIa study are continuing 
to receive RG6042 as part of an “open-label extension” study 
run by Ionis. This study assesses the safety and tolerability of 
longer term dosing of RG6042. A randomized, double-blind, 
Phase III trial to evaluate the efficacy and safety of RG6042 
treatment given once per month or once every 2 months (bi-
monthly) over a period of 25 months (~2 years) is expected 
to start enrolling patients in 2019.76
Ionis Pharmaceutical investigators and their partner, 
Roche, are hypothesizing that a 40% reduction of protein in 
the CSF is indicative of sufficient huntingtin-lowering in the 
brain for clinical efficacy, as indicated by their proceeding to 
invest in further trials aimed at efficacy. What is known from 
animal models regarding the amount of mutant huntingtin-
lowering needed for efficacy?
By how much must mutant huntingtin 
be lowered for a treatment to be 
efficacious?
Numerous studies in rodent models of HD support the 
efficacy of reducing mutant huntingtin mRNA and protein 
levels in the brain for improving the disease phenotype, 
whether using ASOs, siRNAs, shRNAs, miRNAs, or other 
approaches. Partial reversal of disease progression and 
delayed motor dysfunction was achieved in the severely 
affected R6/1 transgenic mice by intrastriatal AAV5-medi-
ated delivery of anti-Htt shRNA which lowered levels of 
mHTT mRNA in the striatum by 78% and protein levels by 
28%.77 Also, using AAV to deliver RNAi constructs to the 
striatum, Boudreau et al78 showed that a 75%  reduction of 
human mHTT and endogenous wild-type mouse Htt mRNA 
levels was well-tolerated and prevented motor and neuro-
pathological deficits in HDN171-82Q mice. Harper et al79 
found that a more modest 51%–55% reduction in mHTT 
mRNA in these HDN171-82Q mice was also sufficient for 
phenotypic benefit, resulting in significant improvements 
in gait deficits and rotarod performance. Along the same 
lines, lentiviral delivery of inhibitory RNAs in a rat model 
of HD that conferred just a 35% knockdown of huntingtin 
gene expression of both mutant and wild-type alleles was 
shown to be safe and provided both neuroanatomical and 
behavioral benefits up to to 9 months after injection.80 
Using ASOs, Kordasiewicz et al81 report that reduction of 
the expression of human mutant exon1 mRNA in the R6/2 
mouse brain by 43% (±5%) was sufficient to prevent further 
brain weight loss and significantly extend the lifespan of 
these severely affected mice. They also reported that reduc-
tion in mHTT mRNA and protein levels in 6-month-old 
YAC128 mice by 58% and 56% (ie, to 42% and 44% of 
controls, respectively) restored their motor deficits to the 
performance level of nontransgenic controls.81 Similarly, 
Stanek et al82 found that reduction of both wild-type and 
mutant huntingtin by ~40% in YAC128 mice resulted in 
significant improvements in behavioral deficits, with no 
notable overt neurotoxicity.
Unfortunately, because the various rodent models differ 
in the nature of their mutant allele (number of CAGs, full 
length or exon1 only, transgenic or knockin, etc), the number 
of wtHTT alleles in their genotype, the level of expres-
sion of mHTT, and the severity of their phenotype, any 
numerical extrapolation from these findings to the human 
case is fraught with uncertainty even ignoring the species 
difference between rodents and humans. For example, the 
YAC128 mouse expresses its full-length 128 CAG-repeat 
mHTT transgene at about 75% of endogenous mouse Htt 
levels and manifests a disease phenotype,83 suggesting that 
a 25% reduction in mHTT mRNA might not be sufficient as 
a therapy. However, a lowering of mHTT by an intervention 
may have different effects than the lowering due to a genetic 
difference. On the other hand, even in a mouse model with 
a severe phenotype (R6/2), reduction of mRNA expression 
by 43% extended the animal’s lifespan. Therefore, there is 
reason to be hopeful that the level of huntingtin-lowering 
attainable by the ASOs, RNAi agents, and other approaches 
progressing toward or in clinical trials will be sufficient 
for therapeutic benefit, if the delivery of the agent to key 
regions of the brain is adequate.
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Timing of huntingtin-lowering: how early 
to start treatment?
Because HD is a progressive disease and individuals needing 
treatment can be positively identified, it would seem desir-
able to start treatment as early in life as can be safely done. 
However, some animal data suggest a need for caution with 
regards to huntingtin-lowering treatments. For example, 
a knockout of wtHTT in mice at 2 months of age (early 
adulthood) produced acute pancreatitis.55 This may not pose 
an issue for treatments in which wtHTT is lowered but not 
eliminated, particularly for treatments delivered directly to 
the central nervous system (CNS) with minimal “spill over” 
and persistence systemically. Other studies in mice have 
found that wtHtt is important for brain development,19,84 and 
if wtHtt levels have been low during a developmental period, 
restoration of wtHtt levels at a later age does not compensate 
for the ill effects of an earlier deficiency.47 These findings 
suggest that except in the case of juvenile HD (in which the 
benefit may outweigh the risks), perhaps treatment should not 
be initiated in people before they are in their early twenties. In 
most cases, this precaution would still allow treatment to be 
initiated many years before predicted clinical symptom onset.
Timing of huntingtin-lowering: how long 
is long enough?
Because HD is a chronic and progressive neurodegenera-
tive disease, it is unrealistic to expect that a short course of 
huntingtin-lowering treatment will be curative – a successful 
huntingtin-lowering treatment will be a life-long endeavor. 
However, preclinical studies of huntingtin-lowering using 
siRNA or ASOs support the conclusion that the administra-
tion of the treatment need not be continuous. The lowering 
of HTT mRNA in primate brain has been found to persist for 
weeks beyond the cessation of delivery of “naked” siRNA 
into the tissue, even though the siRNA itself was not specially 
synthesized or encapsulated to prevent its degradation.62 
More importantly, Kordasiewicz et al81 showed that transient 
administration of ASOs in HD transgenic mice was able to 
degrade HTT mRNA and elicit phenotypic improvements that 
persisted beyond the period of not only ASO administration 
but also mRNA lowering. This has led to the interpretation 
that cells can benefit from a “huntingtin holiday”, whereby 
transient lowering of huntingtin expression enables com-
pensatory mechanisms (yet to be fully delineated) to “catch 
up” so cells can better handle the re-expressed huntingtin.85 
This observation has supported the use of periodic rather 
than continuous administration of ASOs in the trials of 
IONIS-HTT
RX
. In the case of huntingtin-lowering agents 
that can be delivered using viral vectors (shRNA, miRNA, 
intrabodies), continuous and perhaps lifelong delivery of the 
treatment will be a function of the persistence of expression 
of the delivered transgene. Finally, despite the other hurdles 
faced by DNA editing approaches (eg, CRISPR-based gene 
editing), the treatment is expected to be permanent, at least 
in the cells transduced by the agent.
when both wtHTT and mHTT are 
lowered, will the net result be beneficial?
Development of therapies involving non-allele-specific 
huntingtin-lowering is based on the hypothesis that the net 
result of lowering both wtHTT and mHTT in a patient will be 
beneficial. If either an allele-specific or a non-allele-specific 
agent results in lowering of mHTT protein to a greater extent 
than it lowers wtHTT protein, there is reason to believe this 
would be beneficial. Becanovic et al86 have studied samples 
of patients with very early or very late age of disease onset 
relative to the age of onset expected from their CAG repeat 
numbers, and identified a SNP in the promoter region of HTT 
that results in the lowering of expression of the huntingtin 
protein on the cis-allele. If that allele is the mutant allele, 
mHTT protein is lowered relative to wtHTT, and this lowering 
is associated with a delayed age of onset. Conversely, if the 
SNP variant is on the non-expanded allele, wtHTT protein 
is lowered relative to mHTT protein, and the lowering is 
associated with an earlier age of onset.
In a study identifying allele-selective ASOs in a human-
ized mouse model of HD, Southwell et al87 reported that a 
non-allele-selective ASO resulted in reduced levels of HTT 
with maintenance of the basal wild type to mutant protein 
ratios in all areas of the CNS examined. Over the long term, 
what if mHTT might accumulate disproportionately to 
wtHTT due to differences in the efficiency of proteosome 
degradation of the expanded repeat protein? A study of adult-
onset HD brain samples88 found that even though there was a 
small but significantly lower expression of mutant huntingtin 
mRNA compared to wild-type mRNA, wild type and mutant 
protein levels did not differ significantly. In contrast, Liu et 
al89 reported finding that mutant huntingtin mRNA exceeds 
wild-type mRNA in post-mortem HD brains. An assay for 
total HTT in CSF, if available for use in the next human trial 
of IONIS-HTTRX, will answer the question about propor-
tionate huntingtin-lowering. 
The observations that wtHTT stimulates BDNF transcrip-
tion49 and modulates anxiety and depression-like behaviors in 
mice,90 among other observations, suggest that loss of wtHTT 
function could be part of the pathogenesis of the disease. If 
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both mHTT and wtHTT are lowered by an amount sufficient 
for efficacy, will the net result be beneficial? Studies showing 
the tolerability of huntingtin-lowering by ~45% in wild-type 
animals do not address this question, because this result is 
not in the context of a co-expressed mutant protein. Studies 
showing benefit of non-allele-specific huntingtin-lowering in 
mouse models of HD (eg, Boudreau et al78) also do not address 
this question to the extent that in these models the mutant 
transgene is overexpressed, or expressed in the presence of two 
copies of the wild-type murine Hdh. The humanized Hu97/18 
mouse expresses full-length human and mutant huntingtin 
at similar endogenous levels,91 but to our knowledge the net 
effect of long-term non-allele-specific huntingtin-lowering on 
the phenotype of this mouse has not been reported.) Induced 
pluripotent cell lines (iPS cells) derived from HD patients 
and stably transduced with shRNA non-allele specifically 
lowering HTT have been generated and are viable, but the 
benefit of huntingtin-lowering in these cells is unclear.92 
Lowering HTT by 50%–60% in these cells has no beneficial 
effect on the level of p53 protein nor the functioning of the 
MAP kinase signaling pathway, two aspects of the abnormal 
phenotype of these cells. Conversely, Trager et al93 found that 
lowering HTT by ~50% restores normal cytokine function in 
patient-derived monocytes. However, it remains unknown as 
to whether non-allele-specific huntingtin-lowering by ~50% 
will restore cells of the CNS to normalcy.
Summary and conclusion
This review supports several conclusions about huntingtin-
lowering. It is clear that it is possible to lower huntingtin 
in vivo in rodents, sheep, pigs, and non-human primates 
using agents that could be administered to humans, such 
as shRNA, miRNA, ASOs, zinc fingers, and CRISPR/Cas9 
gene editing agents. With some agents, it is possible to 
lower mutant huntingtin in an allele-selective manner. The 
lowering of mutant huntingtin by various means is effica-
cious at improving the abnormal phenotype in many rodent 
models of HD. In rodents, genetic reduction of wtHTT by 
50% or more adversely affects the developing brain, and 
near elimination of wild-type huntingtin is detrimental 
even if not initiated until adulthood. Lowering wild-type 
huntingtin by ~45% in the adult non-human primate stria-
tum is well-tolerated for at least 6 months. Four months of 
periodic administration of a non-allele-specific ASO that 
lowers the level of mutant huntingtin detected in the CSF is 
safe and well-tolerated in patients, and longer term studies 
of the tolerability of the same ASO in primates are report-
edly underway. In mice, some adverse effects of wtHTT-
lowering (eg, thalamic calcification) take 9 months to a 
year to emerge, indicating that long-term preclinical studies 
of the safety of huntingtin-lowering are advisable, even as 
human trials are proceeding. It is notable that the adverse 
effects in mice are the result of huntingtin-lowering to the 
point of near elimination, rather than the more moderate 
lowering typically achieved with clinically relevant agents. 
Collectively, the evidence indicates that the potential adverse 
effects of wild-type huntingtin-lowering are age, amount, 
and perhaps brain region-specific (to the extent that near 
elimination of Htt in wild-type mice eventually resulted in 
calcification, specifically in the thalamus).57 For now, what 
can be concluded is that for safety, huntingtin-lowering in 
the human disease should be either limited in the amount by 
which huntingtin is lowered (eg, preserving about 50% of 
wild-type expression), limited to the most affected regions of 
the brain (ie, the striatum and cortex, and probably avoiding 
in particular the thalamus), or allele-specific, or all of the 
above. This statement is dissatisfying relative to the desire 
for parsimony in the interpretation of evidence, but it is not 
unrealistic given that the disease itself is age, region, and 
dose (CAG repeat number) specific.
Other important questions about huntingtin-lowering 
remain open. Non-allele-specific lowering of huntingtin in 
patients has been found to be safe, but whether it will be 
safe over the long term remains unknown. Also, it remains 
to be seen whether IONIS-HTT
RX
 given via a lumbar route 
of administration penetrates not only the cortex but also the 
caudate nucleus and putamen of patients sufficiently for 
clinical efficacy. It is possible that huntingtin-lowering only 
in the cortex could have some benefit – in rodents, selec-
tive expression of mHTT only in striatal neurons produces 
cell-autonomous deficits in striatal electrophysiology, but 
spares the animal locomotor deficits and striatal degenera-
tion.94 However, HD is a multi-system disease.95 Huntingtin-
lowering in at least both the cortex and the striatum may be 
necessary in the human disease. It remains to be seen whether 
miRNA against huntingtin delivered by AAV5 to the striatum 
(as planned by uniQure) will be transported retrogradely to 
the cortex sufficiently to lower huntingtin in layer V cortical 
neurons projecting to the striatum, and whether other sero-
types of AAV can deliver miRNA against huntingtin across 
the blood–brain barrier sufficiently for a systemic route of 
delivery to be feasible for clinical use in patients. Answers 
to most of these questions will only be provided by clinical 
trials over the next several years.
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What gaps in our knowledge about huntingtin-lowering 
should be pursued by preclinical research in the meantime? A 
fundamental question is whether lowering wild-type hunting-
tin in layer V cortical neurons in particular (not just generally 
in cortical tissue) and thus the corticostriatal connections to 
the striatum will be tolerated in the primate brain. Studies in 
BACHD mice96,97 have indicated that huntingtin-lowering in 
both cortical neurons and the striatum is likely to be necessary 
for optimal treatment efficacy. However, other studies have 
shown that wtHTT functions to promote the production of 
BDNF,49 and transport of BDNF to the striatum is slowed53 
when wtHTT is lowered. So far, studies in non-human pri-
mates showing that lowering of wtHTT is well-tolerated have 
not measured and demonstrated huntingtin-lowering specifi-
cally in layer V cortical neurons whose efferents form the 
corticostriatal tract. Studies using treatment delivery methods 
that achieve simultaneous lowering of huntingtin in both the 
striatum and the cortical neurons projecting to it are needed 
to establish whether reducing wtHTT by about 40%–50% 
in the corticostriatal pathway has adverse effects on BDNF 
levels or otherwise adversely effects the functioning of stria-
tal neurons. If so, this would indicate that an allele-specific 
approach will be necessary.
To our knowledge, the use of patient-derived embryonic 
stem cells or iPS cells to address the question of whether 
lowering of both wild-type and mutant huntingtin results in 
a net benefit at the cellular level has not been fully exploited, 
particularly in cells differentiated to a phenotype resembling 
cortical neurons or medium spiny neurons of the striatum. 
Also, so far, huntingtin-lowering studies in non-human pri-
mates have not been long enough or inclusive of the thalamus 
enough to cover another knowledge gap – whether lowering 
of wtHTT by a clinically relevant amount in the thalamus of 
the primate brain will eventually result in thalamic calcifica-
tion, as seen in mice.57
Although many open questions and hurdles remain, much 
progress is being made toward a huntingtin-lowering therapy 
for HD. Scientists, clinicians, patients, and their families 
can look forward with interest to further developments in 
this field.
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